Clinical

Dataset Information

0

FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients


ABSTRACT: The scope of this study is to evaluate the efficacy of the addition of atezolizumab to FOLFOXIRI plus bevacizumab as first line treatment of patients with metastatic colorectal cancer in terms of Progression Free Survival.

DISEASE(S): Metastatic Colorectal Cancer,Colorectal Neoplasms,Carcinoma Colorettale Metastatico

PROVIDER: 2288021 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2181974 | ecrin-mdr-crc
| 2182846 | ecrin-mdr-crc
| 2369422 | ecrin-mdr-crc
| 2284699 | ecrin-mdr-crc
| 2165831 | ecrin-mdr-crc
| 2210014 | ecrin-mdr-crc
| 2625826 | ecrin-mdr-crc
| 2195502 | ecrin-mdr-crc
| S-EPMC6251034 | biostudies-literature
| S-EPMC7905498 | biostudies-literature